Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This randomized phase III trial studies first-line chemotherapy and trastuzumab to compare
how well they work when given with or without bevacizumab in treating patients with breast
cancer that overexpresses human epidermal growth factor receptor 2 (HER-2/NEU) and has spread
to other areas of the body. Drugs used in chemotherapy, such as paclitaxel and carboplatin,
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such
as trastuzumab and bevacizumab, may interfere with the ability of tumor cells to grow and
spread. Bevacizumab may also stop the growth of breast cancer by blocking the growth of new
blood vessels necessary for tumor growth. It is not yet known whether giving first-line
chemotherapy together with trastuzumab is more effective with or without bevacizumab in
treating patients with metastatic breast cancer that overexpresses HER-2/NEU.